Shifting to a Systemic Approach
What does the future hold for the management – and treatment – of diabetic eye disease?
Anat Loewenstein | | Opinion
The prevalence of diabetic eye diseases is increasing worldwide. Given that diabetic macular edema (DME) is a major cause of vision loss in diabetes patients, screening is more important than ever. Thankfully, a number of artificial intelligence systems have been developed in recent years for autonomous detection of diabetic retinopathy (DR) and DME, including the IDx system, which can be used to detect DR with a sensitivity of 87.2 percent and a specificity of 90.7 percent.
The test only takes a few minutes and can be done in the primary care physician’s office, increasing our ability to detect disease early – and it provides diagnostic interpretation and care instructions aligned with American Academy of Ophthalmology guidelines for DR. In April 2018, IDx-DR was approved by the FDA for the detection of greater than mild level of DR in adults who have diabetes and can now be found in endocrinology clinics, internal medicine clinics, diabetes education centers, diagnostic labs, community health clinics and diabetes research groups (1).
Read the full article now
Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Ophthalmologist magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.